DGAP-News: SYGNIS AG

PRESS RELEASE
24 October 2017

SYGNIS AG announces the launch of the Universal Lateral Flow Assay kit and associated patent filing

Unique kit enables the fast and easy development of customised sandwich lateral flow assays

Madrid, Spain and Heidelberg, Germany, 24 October 2017 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of its Universal Lateral Flow Assay (LFA) kit, the latest addition to its expanding range of lateral flow assay products and services which are being commercialised under the Innova Biosciences brand name. The novel product provides a tool for the easy, quick development of customised sandwich lateral flow assays. This enables researchers to rapidly progress the R&D of their point-of-care (POC) diagnostic tools thereby providing physicians with faster access to POC testing for rapid early detection of disease. The Company has filed a patent application to protect its newly developed product and technology.

The global market for lateral flow assays is growing at 16% per annum and projected to be worth US $ 8.2 billion by 2022. This growth is driven by the rising demand for point-of-care testing and the high prevalence of infectious diseases worldwide. The launch of the Universal LFA kit enables researchers to streamline the R&D of their diagnostic tests, enabling rapid development of POC diagnostic tools for entry into this growing market.

The kit utilises the Company's world leading patented antibody labelling technologies Lightning-Link^(R) and InnovaCoat^(R) GOLD, and enables customers to create lateral flow assay reagents with only a few minutes of hands-on time, without the need to spray down capture antibodies on the test strip, a labour-intensive process that consumes large amounts of expensive antibody reagent.

The Lightning-Link^(R) technology within the Universal LFA kit enables quick and easy labelling of up to three analyte capture antibodies of the customers' choice whilst InnovaCoat^(R) Gold technology is used for covalent conjugation of up to three detection antibodies to ultra-high-quality gold nanoparticles, thereby providing complete flexibility to the customer offering the ability to optimise a personalised lateral flow assay in a few days instead of weeks.

Dr. Nick Gee, CTO at SYGNIS, commented: "The launch of the Universal Lateral Flow Assay kit is a novel addition to SYGNIS' rapidly expanding range of lateral flow assay products and services. This new kit massively simplifies and accelerates assay development in addition to reducing costs, ultimately benefiting anyone that works with lateral flow assays."

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG
Dr. Claudia Gutjahr-Loeser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG develops and commercialises value-added, easy-to-use, reliable products based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With the acquisitions of Expedeon Holdings, Ltd. in 2016 and both C.B.S. Scientific Company, Inc. and Innova Biosciences Ltd. in 2017, SYGNIS significantly expanded its product line and now covers the entire molecular biology workflow, including genomics, proteomics and tools as well as cutting-edge bioconjugation technologies and services. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. The SYGNIS Group has offices in Germany, Spain and the UK; production sites in the UK and the U.S. and sales offices in Asia. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###